ZVRA Jun 2024 5.000 call
| Previous close | 0.1400 |
| Open | 0.1000 |
| Bid | 0.0500 |
| Ask | 0.2000 |
| Strike | 5.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.1000 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 474 |
GlobeNewswireZevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog Additional data presented on pharmacokinetics of morning and nighttime doses of KP1077 European Commission has granted Orphan Drug Designation for KP1077 for the treatment of idiopathic hypersomnia CELEBRATION, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics
Simply Wall St.Retail investors account for 59% of Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) ownership, while institutions account for 28%
Key Insights Significant control over Zevra Therapeutics by retail investors implies that the general public has more...
Insider MonkeyZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript May 8, 2024 Zevra Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, everyone. Thank you for joining the Zevra Therapeutics’ First Quarter 2024 Corporate Update and Financial […]
